Early isolated central nervous system relapse of mantle cell lymphoma successfully treated with ibrutinib and CAR T-cell therapy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F25%3A10159782" target="_blank" >RIV/00098892:_____/25:10159782 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/25:73634883

Výsledek na webu

<a href="https://redakce.carecomm.cz/tahd/cs/article/view/3023" target="_blank" >https://redakce.carecomm.cz/tahd/cs/article/view/3023</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.48095/cctahd202526" target="_blank" >10.48095/cctahd202526</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Early isolated central nervous system relapse of mantle cell lymphoma successfully treated with ibrutinib and CAR T-cell therapy

Popis výsledku v původním jazyce

Mantle cell lymphoma (MCL) is a relatively rare and clinically distinct subtype of non-Hodgkin lymphoma. Involvement of the central nervous system is an uncommon manifestation at both diagnosis and recurrence. Central nervous system (CNS) relapse more frequently occurs in the context of aggressive dis ease behaviour and portends a poor prognosis. However, advances in therapeutic strategies for MCL have opened the possibility of achieving durable remission, even in this high-risk presentation. We report a case of a patient who developed an early, isolated CNS relapse following autologous stem cell transplantation. The patient was successfully treated with a sequential treatment protocol combining chemoimmunotherapy, ibrutinib and chimeric antigen receptor T-cell therapy.

Název v anglickém jazyce

Early isolated central nervous system relapse of mantle cell lymphoma successfully treated with ibrutinib and CAR T-cell therapy

Popis výsledku anglicky

Mantle cell lymphoma (MCL) is a relatively rare and clinically distinct subtype of non-Hodgkin lymphoma. Involvement of the central nervous system is an uncommon manifestation at both diagnosis and recurrence. Central nervous system (CNS) relapse more frequently occurs in the context of aggressive dis ease behaviour and portends a poor prognosis. However, advances in therapeutic strategies for MCL have opened the possibility of achieving durable remission, even in this high-risk presentation. We report a case of a patient who developed an early, isolated CNS relapse following autologous stem cell transplantation. The patient was successfully treated with a sequential treatment protocol combining chemoimmunotherapy, ibrutinib and chimeric antigen receptor T-cell therapy.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Transfuze a hematologie dnes

ISSN

1213-5763

e-ISSN

1805-4587

Svazek periodika

31

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

311-315

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-105028566250